CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with ...

ZIBO CITY, SHANDONG PROVINCE, CHINA, March 5, 2026 /EINPresswire.com/ -- The global ceramic fiber market has grown ...

Emerita Resources Corp. (TSX-V: EMO; OTCQX: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) is pleased to announce results ...

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

From hypersonic aircraft to nuclear-powered submarines, many of today's most advanced defense systems rely on a special class of materials known as refractory alloys. This class refers to metals that ...

Chief Executive Officer Christian Itin told conference attendees the company is entering its second year as a commercial-stage business following the launch of its first product, obe-cel, a CD19 CAR-T ...

Although physiological immune responses require increased tissue vasculature, many solid tumors simultaneously activate angiogenesis to meet the increasing demand for oxygen and nutrients while ...

Victory Metals’ first pass sighter flotation has successfully upgraded the total rare earth oxide concentration of raw ore ...

Emerita Resources Corp. (TSX-V: EMO; OTCQX: EMOTF; FSE: LLJA) (the "Company" or "Emerita") is pleased to announce results from metallurgical tests using the ...

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...

QINGDAO, SHANDONG, CHINA, January 28, 2026 /EINPresswire.com/ -- In the context of rapid global infrastructure and ...